IRIS
STORTI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.294
EU - Europa 2.109
AS - Asia 1.094
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 6
OC - Oceania 2
SA - Sud America 1
Totale 5.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.257
CN - Cina 870
SE - Svezia 531
IE - Irlanda 499
FI - Finlandia 365
IT - Italia 273
DE - Germania 181
TR - Turchia 154
UA - Ucraina 78
AT - Austria 53
CA - Canada 36
RO - Romania 34
BE - Belgio 29
SG - Singapore 27
IN - India 26
GB - Regno Unito 16
FR - Francia 15
EU - Europa 9
NL - Olanda 9
CZ - Repubblica Ceca 5
IR - Iran 5
BG - Bulgaria 4
HK - Hong Kong 3
RU - Federazione Russa 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CM - Camerun 2
ES - Italia 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
PT - Portogallo 2
SC - Seychelles 2
SM - San Marino 2
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
CO - Colombia 1
DK - Danimarca 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
PK - Pakistan 1
RS - Serbia 1
TW - Taiwan 1
Totale 5.515
Salva come PNG Salva come JPEG
Città #
Chandler 538
Dublin 499
Beijing 211
Ashburn 168
Jacksonville 157
Ann Arbor 145
Parma 145
Izmir 138
Nanjing 133
Dearborn 125
Princeton 90
New York 73
Shanghai 72
San Mateo 62
Kunming 57
Vienna 53
Shenyang 52
Wilmington 50
Nanchang 38
Hebei 34
Toronto 33
Düsseldorf 32
Jiaxing 32
Jinan 30
Bremen 29
Brussels 29
Tianjin 29
Helsinki 28
Hefei 25
Des Moines 23
Focsani 22
Los Angeles 22
Changsha 20
Seattle 16
Boardman 15
Hangzhou 15
Kocaeli 15
Pune 14
Woodbridge 14
Norwalk 13
Redmond 12
Zhengzhou 12
Milan 10
Chengdu 9
Jesi 9
Taizhou 9
Guangzhou 8
Houston 8
Fuzhou 7
Fairfield 6
Mestre 6
Palermo 6
Rockville 6
Bologna 5
Chongqing 5
Modena 5
Ningbo 5
Borås 4
Cambridge 4
Chicago 4
Fremont 4
Haikou 4
Rho 4
Savignano sul Rubicone 4
Sofia 4
Timisoara 4
Washington 4
Ahmedabad 3
Catania 3
Cesena 3
Huizen 3
Leawood 3
Nürnberg 3
Reggio Emilia 3
St Louis 3
Taiyuan 3
Wuhan 3
Arcevia 2
Baotou 2
Boston 2
Central 2
Chisinau 2
Cornaredo 2
Dubai 2
Edinburgh 2
Geislingen an der Steige 2
Grafing 2
Jinhua 2
Lagos 2
London 2
L’Aquila 2
Madrid 2
Nerviano 2
Old Bridge 2
Orange 2
Ottawa 2
Piacenza 2
Pilastro 2
Quzhou 2
Redwood City 2
Totale 3.540
Salva come PNG Salva come JPEG
Nome #
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 97
Are the Myeloma bone microevironment cells tumoral or not? 94
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 93
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 92
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 91
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 89
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 89
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 89
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 89
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 87
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 84
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 83
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 82
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 82
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 81
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 79
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 78
Possible targets to treat myeloma-related osteoclastogenesis 77
Novel targets for the treatment of relapsing multiple myeloma 77
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 76
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 74
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 74
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 74
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 74
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 73
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 72
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 72
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 72
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 71
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 71
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 69
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 68
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 66
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 66
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 65
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 65
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 64
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 64
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 63
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 63
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 63
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 62
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 62
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 62
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 61
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 61
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 61
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 61
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 60
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 60
Angiogenesis and multiple myeloma 60
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 59
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 59
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 58
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 58
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 57
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES 57
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 56
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 56
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 55
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 53
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 53
Comet assay and prediction of clinical outcome after DNA-damaging drugs treatment 52
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 51
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 51
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 50
Role of Galectins in Multiple Myeloma. 50
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 50
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 49
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 49
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 49
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 48
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 48
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 47
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 47
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 46
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 45
Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts 44
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 44
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 44
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 43
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 43
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 42
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 41
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 40
Is there a way to predict the clinical outcome of DNA strand breaks generating drugs? The case of calicheamicin 39
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 37
Detection of DNA strand breaks as individual predictive response to Gemtuzumab Ozogamicin in acute myeloid leukaemia 33
The impact of CD56 expression in smoldering myeloma patients on early progression 30
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 23
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 20
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 20
The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged 20
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 18
Totale 5.696
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.776
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019211 0 0 0 0 0 0 0 0 0 17 170 24
2019/20201.091 222 269 39 13 49 100 105 24 70 113 39 48
2020/2021464 33 37 20 10 76 10 26 23 110 32 50 37
2021/2022491 14 9 15 42 13 10 67 55 19 42 39 166
2022/20232.037 213 229 152 148 168 227 66 137 599 25 56 17
2023/2024581 30 71 14 19 55 215 77 34 21 45 0 0
Totale 5.696